Compare ZWS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZWS | TGTX |
|---|---|---|
| Founded | 1900 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 7.9B |
| IPO Year | 2008 | 2008 |
| Metric | ZWS | TGTX |
|---|---|---|
| Price | $47.74 | $56.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $53.67 | $49.80 |
| AVG Volume (30 Days) | 650.6K | ★ 1.9M |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | 25.00 | ★ 1746.67 |
| EPS | ★ 0.35 | 0.17 |
| Revenue | ★ $1,530,500,000.00 | $2,785,000.00 |
| Revenue This Year | $6.90 | $49.08 |
| Revenue Next Year | $5.13 | $26.69 |
| P/E Ratio | ★ $136.16 | $337.06 |
| Revenue Growth | ★ 19.40 | N/A |
| 52 Week Low | $43.06 | $26.76 |
| 52 Week High | $55.00 | $59.30 |
| Indicator | ZWS | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 63.39 |
| Support Level | $45.92 | $51.22 |
| Resistance Level | $48.54 | $58.04 |
| Average True Range (ATR) | 0.88 | 2.67 |
| MACD | -0.32 | 0.57 |
| Stochastic Oscillator | 27.86 | 88.26 |
Zurn Elkay Water Solutions Corp is a growth-oriented, pure-play water management business that designs, procures, manufactures, and markets the broadest sustainable product portfolio of specification-driven water management solutions to improve health, hydration, human safety and the environment. Its product portfolio includes professional grade water safety and control products, flow systems products, hygienic and environmental products, and filtered drinking water products for public and private spaces that deliver superior value to building owners, positively impact the environment and human hygiene and reduce product installation time.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.